Sodium t-butoxide → 5-(5-Bromo-imidazo[1,2-a]pyrazin-8-ylamino)-pyridine-2-carboxylic acid (2-diethylamino-ethyl)-amide

HRID 1366126

Reaktionsgleichung

Reaktionsgleichung von HRID 1366126
OC1C=CC(C[NH:7]C(=O)C2C=CC(NC3C4N(C=CN=4)C(C4C=NNC=4)=CN=3)=CC=2)=CC=1.[Br:33][C:34]1[N:39]2[CH:40]=[CH:41][N:42]=[C:38]2[C:37](Br)=[N:36][CH:35]=1.[CH2:44]([N:46]([CH2:59][CH3:60])[CH2:47][CH2:48][NH:49][C:50]([C:52]1[CH:57]=[CH:56][C:55]([NH2:58])=[CH:54][N:53]=1)=[O:51])[CH3:45].CC([O-])(C)C.[Na+]>C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd].CC1(C)C2C(=C(P(C3C=CC=CC=3)C3C=CC=CC=3)C=CC=2)OC2C(P(C3C=CC=CC=3)C3C=CC=CC=3)=CC=CC1=2.C1(C)C=CC=CC=1>[NH3:7].[CH2:59]([N:46]([CH2:44][CH3:45])[CH2:47][CH2:48][NH:49][C:50]([C:52]1[CH:57]=[CH:56][C:55]([NH:58][C:37]2[C:38]3[N:39]([CH:40]=[CH:41][N:42]=3)[C:34]([Br:33])=[CH:35][N:36]=2)=[CH:54][N:53]=1)=[O:51])[CH3:60]

Komponenten

9

Versuchsvorschrift

In the same way as described for Compound 90, step 1, using 5,8-dibromoimidazo[1,2-a]pyrazine (0.272 g, 0.982 mmol), 5-amino-pyridine-2-carboxylic acid (2-diethylamino-ethyl)-amide (0.197 g, 0.835 mmol), NaOtBu (0.132 g, 1.37 mmol), Pd2(dba)3 (18 mg, 0.02 mmol), Xantphos (22 mg, 0.038 mmol) and toluene (3 mL). The crude material is purified by silica gel column chromatography eluting with DCM followed by 94:6 DCM:NH3 (7M in MeOH) to afford the title compound (0.263 g, 72%). HPLC (254 nm) Rt 2.09 min (72%).

Aufarbeitung

  1. customThe crude material is purified by silica gel column chromatography
  2. washeluting with DCM

Quellen und Nachweise

ORD-Eintrag
ord-645031713f7447d1b96085545a24359c
Quelldatensatz
uspto-grants-2011_02
Patentnummer
US07893058B2

Verknüpfte Notizen

Wird geladen…